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Abstract
Background: Blood pressure (BP) has significant heritability, but the genes responsible remain
largely unknown. Single nucleotide polymorphisms (SNPs) at the STK39  locus were recently
associated with hypertension by genome-wide association in an Amish population; in vitro data from
transient transfection experiments using reporter constructs suggested that altered STK39
expression might mediate the effect. However, other large studies have not implicated STK39 in
hypertension. We determined whether reported SNPs influenced STK39 expression in vivo, or
were associated with BP in a large British Caucasian cohort.
Methods: 1372 members of 247 Caucasian families ascertained through a hypertensive proband
were genotyped for reported risk variants in STK39 (rs6749447, rs3754777, rs35929607) using
Sequenom technology. MERLIN software was used for family-based association testing. Cis-acting
influences on expression were assessed in vivo using allelic expression ratios in cDNA from
peripheral blood cells in 35 South African individuals heterozygous for a transcribed SNP in STK39
(rs1061471) and quantified by mass spectrometry (Sequenom).
Results: No significant association was seen between the SNPs tested and systolic or diastolic BP
in clinic or ambulatory measurements (all p > 0.05). The tested SNPs were all associated with allelic
expression differences in peripheral blood cells (p < 0.05), with the most significant association for
the intronic SNP rs6749447 (P = 9.9 × 10-4). In individuals who were heterozygous for this SNP,
on average the G allele showed 13% overexpression compared to the T allele.
Conclusions: STK39 expression is modified by polymorphisms acting in cis and the typed SNPs
are associated with allelic expression of this gene, but there is no evidence for an association with
BP in a British Caucasian cohort.
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Background
Hypertension is a major risk factor for vascular and renal
disease and thereby contributes to substantial worldwide
morbidity and mortality [1]. Although blood pressure
(BP) has been shown to have significant heritability (30-
60%) [2], the genes conferring susceptibility to hyperten-
sion remain largely unknown. A recent genome-wide
association study (GWAS) analysed 79,447 single-nucle-
otide polymorphisms (SNPs) in the American Old Order
Amish, a closed population descended from a small
number of common founders who emigrated from Swit-
zerland in the early 1700s who have a relatively homoge-
neous lifestyle [3]. Their initial genome-wide screen of
542 subjects from the Amish Family Diabetes Study [4], in
which families were ascertained through a proband with
type 2 diabetes, identified a cluster of SNPs in the STK39
(serine threonine kinase 39) locus on chromosome
2q24.3 that were associated with BP (P = 8.9 × 10-6 to 9.1
× 10-5) [3]. Although the P-value did not reach the con-
ventionally accepted threshold for genome-wide signifi-
cance [5], the inclusion of additional data from an Amish
and four non-Amish Caucasian cohorts led to a significant
result (P = 1.6 × 10-7) in the combined dataset of 7,125
individuals. The replication cohorts included a further
population of 2,842 individuals from a case-control study
of diabetes and three smaller groups not selected for dia-
betes.
The STK39 gene encodes the SPAK (Ste20-related proline-
alanine-rich kinase) protein which interacts with ion
cotransporters involved in salt transport and osmotic cell
volume regulation, including the thiazide-sensitive and
loop diuretic-sensitive cotransporters involved in renal
salt excretion [6,7]. The STK39 gene contains 18 exons
spanning approximately 300 kb on chromosome 2q24.3;
SNPs associated with BP by GWAS were located within
introns 1-8, with no coding or splice variants identified by
sequencing [3]. Using transfection experiments with luci-
ferase reporter constructs Wang and colleagues demon-
strated that alleles of one SNP (rs35929607), located in a
conserved region of intron 2, altered expression of the
reporter constructs in vitro. This SNP was in linkage dise-
quilibrium (LD) with the SNPs identified by GWAS, sug-
gesting a possible functional mechanism for the observed
association.
Despite these results, other large GWAS and meta-analyses
involving up to 71,225 Caucasian individuals have failed
to identify association between STK39 SNPs and BP that
satisfies genome-wide significance thresholds [8-10].
However, such data do not exclude an effect of this locus
on BP, since the statistical threshold for replicating an
association differs from the threshold for genome-wide
'discovery'. Differences in the actual SNPs genotyped, pat-
terns of LD, and phenotypic variation between popula-
tions might contribute to the lack of genome-wide
significance in these studies, compared to the GWAS by
Wang and colleagues. One recent GWAS looked specifi-
cally for evidence of correlation between STK39 SNPs and
BP in 1017 African American subjects and provided some
supportive evidence for an association [11]. SNPs in the
STK39  region did not reach genome-wide significance,
but the number of significantly associated SNPs at a nom-
inal p threshold of p < 0.05 was somewhat higher than
expected by chance alone (9/136 for systolic BP and 33/
136 for diastolic BP, compared to 7/136 expected by
chance).
We aimed to test whether the STK39 SNPs identified in
the report by Wang and colleagues [3] were associated
with BP in a large family-based Caucasian cohort ascer-
tained through probands with essential hypertension
[12,13]. This cohort has a higher average BP (134 v 128
mmHg systolic) and lower proportion of diabetics (2.5 v
22.2%) compared to the Amish population used for the
initial genome-wide study by Wang and colleagues, but
has 24-hour ambulatory BP recordings which provide a
more reproducible and precise measure of true BP, with
better prediction of cardiovascular events, compared to
clinic BP measures [14,15]. Selecting the same SNPs typed
by Wang and colleagues and using a cohort enriched for
hypertension with ambulatory BP data should increase
the power to detect effects associated with these variants
in our population.
We also aimed to confirm whether the SNPs have cis-act-
ing effects on STK39 expression in vivo using allelic expres-
sion imbalance (AEI). This technique measures the
relative amount of transcript arising from each allele in
individuals heterozygous for a transcribed polymor-
phism. Unequal amounts of transcript from each allele
indicate the presence of cis-acting effects on gene expres-
sion [16]. The allelic expression ratio can be used to quan-
tify the degree of AEI and test whether particular SNPs are
associated with cis-acting effects, even in the absence of
LD between the transcribed and cis-acting SNPs [17]. The
degree to which data from transfection studies in cell lines
represents the in vivo situation in complex human tissues
is questionable [18]. AEI assesses alleles expressed in their
native environment, and because comparison of alleles is
made within samples, trans-acting influences and experi-
mental insults are the same for each allele which maxim-
ises the sensitivity for detecting cis-acting effects [16].
Methods
Association of SNPs with blood pressure
Family ascertainment
1372 members of 247 British Caucasian families ascer-
tained through hypertensive probands and phenotyped
for a quantitative genetic study of cardiovascular risk fac-BMC Medical Genetics 2009, 10:135 http://www.biomedcentral.com/1471-2350/10/135
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tors from 1993-2001 were included. A detailed descrip-
tion of this series and the ascertainment strategy has been
published previously [12]. Briefly, families were selected
through a proband with essential hypertension whose
systolic and diastolic BP were in the top 5% of the popu-
lation distribution (defined as daytime ambulatory BP
>140/90 mmHg; three clinic BP measurements >160/95
mmHg; or treatment with at least two antihypertensive
medications). Secondary hypertension was excluded
using the screening protocol applied in the hypertension
clinic. Families were required to consist of at least three
siblings (including the proband) clinically assessable for
BP if DNA from a parent of the sibship was available, or at
least four siblings if no parental DNA was available. Qual-
ifying sibships could be in the generation of the proband,
or the offspring. There was no requirement for additional
members of the family to be hypertensive, but where addi-
tional members of the sibship were found to have hyper-
tension (using the same criteria), families were extended
and the spouses and offspring of hypertensive members
also collected. The majority (64%) of the individuals in
the family collection therefore have BP within the conven-
tionally accepted "normal range", and the family collec-
tion includes some extended families, though most are
nuclear families. A total of 1425 subjects from 248 fami-
lies were recruited; all 1372 family members in whom
DNA was available were genotyped in the present study.
The median family size was 5 people, 60% of families
comprising between 4 and 6 genotyped and phenotyped
members. 71% of families were 2-generation and 29%
were 3-generation. 84% of families had an assessable sib-
ship in the generation of the proband, while 16% of fam-
ilies consisted of a proband and their nuclear family
(spouse and children over 18 years) only. The study com-
plies with the principles of the Declaration of Helsinki;
informed consent was obtained from all participants and
the study was approved by the Central Oxford Research
Ethics Committee and Newcastle and North Tyneside
Local Research Ethics Committee.
BP measurement
Blood pressure was measured using ambulatory monitor-
ing for a period of 24 hours in all subjects willing to
undergo monitoring, using the A&D TM2421 monitor.
Three readings were taken with the patient in a relaxed
seated position at the start of the monitoring period.
Simultaneous auscultation was carried out by a trained
observer, to confirm satisfactory (within 5 mmHg) agree-
ment between the monitor and auscultatory values; if this
criterion was not met, the cuff was repositioned until sat-
isfactory agreement was obtained. The three readings
which had satisfactory agreement between the monitor
and the observer in the final cuff position are referred to
as "clinic readings". The monitor was programmed to
record blood pressure every half-hour during the daytime
and every hour during the night, and a recording was con-
sidered of satisfactory technical quality if at least 20 day-
time ambulatory data points were available for analysis.
Patients also recorded the time they went to bed and rose
in the morning to enable individualised calculation of the
"daytime" and "night-time" periods. Mean values for
systolic and diastolic blood pressures for the clinic, day-
time and night-time periods were analysed for association
with genotypes.
A full clinical history was taken, which included the sub-
ject's medical history and lifestyle factors including con-
sumption of alcohol and tobacco, and habitual physical
exercise. Anthropometric data including height, weight
and waist and hip circumferences were measured. DNA
was extracted from blood samples using standard meth-
ods.
Genotyping
Four SNPs reported to be associated with hypertension by
Wang and colleagues [3] were selected for genotyping;
three at the STK39  locus on chromosome 2q24.3
(rs6749447, rs3754777 and rs35929607) and one on
chromosome 9p21.3 (rs4977950) which gave the most
significant signal for genome-wide association in the
same study [3].
Multiplex SNP genotyping was performed using PCR fol-
lowed by primer extension and MALDI-TOF mass spec-
trometry using iPLEX Gold technology from Sequenom
(Sequenom Inc, San Diego, USA). SNP assays were
designed using Sequenom's RealSNP http://www.Real
SNP.com and MassARRAY Assay Design v3.0 Software.
Primer sequences and full experimental methods are
available in Additional File 1. Spectra were analysed using
MassARRAY Typer v3.4 Software (Sequenom). Spectra
and plots were manually reviewed and auto-calls were
adjusted if required. Positive and negative controls were
included. Mendelian inheritance and correspondence of
genotype frequencies to Hardy-Weinberg proportions
were tested using PEDSTATS [19].
Statistical analysis
The analysis was performed using log transformed BP val-
ues to approximately normalise the distribution [12].
Adjustments were then made for significant covariates
determined by linear regression, considering age, sex, car-
diovascular medications, smoking status (current/former/
never), alcohol consumption (units per week) and exer-
cise habit (frequency per week). For those participants
taking antihypertensive medication, the effects of the
main drug classes (diuretics and β-blockers) were esti-
mated from the data by regression, and the appropriate
adjustment made to the on-treatment BP values, as previ-
ously described [12]. Association between genotypes andBMC Medical Genetics 2009, 10:135 http://www.biomedcentral.com/1471-2350/10/135
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adjusted phenotypes was assessed using MERLIN v1.1.2
[20,21]. In order to estimate the upper bound of the
genetic effect that is plausibly associated with each pheno-
type/SNP combination, linear regression models were fit-
ted to model additive genetic effects using Minitab v15.
Narrow-sense heritability estimates (and 95% confidence
intervals thereof) were calculated by standard population
genetic formulae. The narrow-sense heritability (h2) of
each phenotype and proportion of phenotypic variation
accounted for by covariates (r2) is shown in Table 1.
Association of SNPs with STK39 allelic expression
Identification of transcribed markers for allelic expression analysis
Allelic expression measures the relative amount of tran-
script arising from each allele in individuals heterozygous
for a transcribed polymorphism. NCBI dbSNP (http://
www.ncbi.nlm.nih.gov, 6th January 2009) was used to
identify SNPs in transcribed regions of STK39 with minor
allele frequencies greater than 5%. Nine transcribed vari-
ants were identified (rs1061471, rs3769429, rs7425806,
rs3769428, rs56330212, rs56697518, rs56031549,
rs1802105, rs56048258). Only two of these had previ-
ously been validated according to dbSNP (minor alleles
observed in at least two chromosomes): rs1061471 in
exon 18 (3' untranslated region) and rs56031549 in exon
11 (missense A/G SNP). Three of the reported variants
(rs7425806, rs3769429 and rs3769428) were non-poly-
morphic in all HapMap populations. SNP rs1061471 was
non-polymorphic in the Caucasian HapMap CEU popula-
tion, but had a minor allele frequency of 11% and inform-
ative heterozygote frequency of 24% in the African
HapMap YRI population. In order to find transcribed
markers suitable for assessing allelic expression, we ana-
lysed rs1061471 and the five markers for which HapMap
population frequencies were not available (rs1802105,
rs56031549, rs56048258, rs56330212, rs56697518) as
described below.
Samples
For expression analysis we chose a cohort collected from
an African population comprising 309 anonymous South
African blood donors (self-reported ethnicity for these
individuals was: Cape Mixed Ancestry 200; black African
67; Indian 30; white 10; other 2). The study complies with
the principles of the Declaration of Helsinki; written
informed consent was obtained from all participants and
the study was approved by the University of Cape Town
Faculty of Health Sciences Research Ethics Committee.
Compared to a Caucasian population such a cohort is
expected to exhibit greater genetic diversity, i.e. an
increase of the probability of obtaining informative sam-
ples (heterozygous for at least one transcribed marker)
and a reduction of the length of blocks with high LD. The
latter will improve the ability to separate the effects of dif-
ferent SNPs on expression. Peripheral blood for DNA and
RNA analysis DNA was extracted using an in-house phe-
nol/chloroform method from 4 ml of peripheral blood in
EDTA. Genotyping was performed on the Sequenom plat-
form (as described above) for rs1061471 and the other
five markers for which HapMap population frequencies
were unknown (rs1802105, rs56031549, rs56048258,
rs56330212, rs56697518). 35 individuals heterozygous
for the transcribed variant rs1061471 and therefore suita-
ble for allelic expression analysis were identified. The
other five SNPs tested had minor allele frequencies <1%,
giving an insufficient number of heterozygotes to be used
for AEI assessment (Additional File 1 Table S2).
For the 35 individuals heterozygous for rs1061471, RNA
was extracted from 2.5 ml of peripheral blood collected
using the PAXgene system (Qiagen) without DNase treat-
ment and eluted into a volume of 80 μl. The RNA solution
was then DNase treated using RQ1 RNase-Free DNase
(Promega). Mean total RNA concentration quantified by
photospectrometry was 166 (± 65) ng/μl in the eluate.
Approximately 2 μg of total RNA was reverse transcribed
Table 1: Clinical and BP characteristics of the Caucasian participants
Characteristic N Median (LQ, UQ) in mmHg Proportion of phenotypic 
variability (r2) explained by covariates 
for log-transformed variable
Heritability (h2) for 
adjusted variable
Hypertension 490 - - -
Current smoker 298 - - -
Diabetes 35 - - -
Structural heart disease 55 - - -
Cardiovascular medication 456 - - -
Clinic Systolic BP 1138 134 (121.3, 152.3) 27.2 11.2
Clinic Diastolic BP 1130 82 (73.7, 92) 19.7 12.2
Day Systolic BP 1134 132.5 (122.1, 146) 20.4 13.6
Day Diastolic BP 1133 79.7 (72.5, 90) 17.9 10.7
Night Systolic BP 903 113 (103.8, 126) 11.4 24.3
Night Diastolic BP 902 66 (60.2, 73.6) 13.6 34.6
N = 1372 Caucasian participants. BP, blood pressure; LQ, lower quartile; UQ, upper quartile.BMC Medical Genetics 2009, 10:135 http://www.biomedcentral.com/1471-2350/10/135
Page 5 of 9
(page number not for citation purposes)
using the SuperScript VILO cDNA Synthesis Kit (Invitro-
gen) and eluted in 20 μl.
Measurement of STK39 allelic expression ratios
Quantification of the allelic expression ratio was per-
formed by uniplex PCR from 1 ul of cDNA followed by
primer extension and MALDI-TOF mass spectrometry
using iPLEX Gold technology from Sequenom (Seque-
nom Inc, San Diego, USA). Primer sequences and full
experimental methods for this are available in Additional
File 1. Allelic ratios were estimated as the ratios of the area
under G and A peaks, and were performed in four repli-
cates from the same cDNA preparation. Results from
amplification of genomic DNA (where alleles are present
in a 1:1 ratio) from 19 individuals (performed in 4 repli-
cates) were used as the equimolar reference to normalise
the cDNA values.
Statistical analysis
Analyses were performed as described by Teare and col-
leagues [17] using the logarithm of the normalised allelic
expression ratios.
Results
Association with blood pressure
1372 individuals were included; 649 (47%) were male,
490 (36%) were hypertensive, and mean age was 49
(standard deviation 15.5) years. The clinical characteris-
tics and BP parameters of participants are shown in Table
1. Median alcohol consumption was 3 (interquartile
range 0-12) units per week. 43% reported no regular exer-
cise per week, with 21%, 22% and 14% exercising once,
twice, and three or more times per week respectively.
Genotyping was complete for more than 99% of individ-
uals at all loci. Allele frequencies for typed SNPs are
shown in Table 2; these were similar to the HapMap CEU
population and did not deviate significantly from Hardy-
Weinberg proportions.
There was no significant association between genotype
and covariate-adjusted, log transformed BP parameters at
the loci studied, using a global P-value of p = 0.05. Esti-
mates of effect size with 95% confidence intervals are
shown in Table 3; the upper bound of the contribution of
typed SNPs to the total population variance was low for
all of the phenotypes tested (ranges: rs3754777 0.4-1.1%;
rs35929607 0.5-1.7%; rs6749447 0.4-1.4%; rs4977950
0.4-0.6%).
Association with allelic expression
Two of the 35 samples failed quality control criteria for
allelic expression measurements at the transcribed SNP
rs1061471 because of high standard error between repli-
cates and were excluded from the analysis; all replicates
for the remaining 33 samples were included. The experi-
mental variability was low and the average standard error
of the log-transformed ratio for the four technical repli-
cates was the same in gDNA (0.0146) and cDNA
(0.0149). The standard deviation of the sample means
(represented in Figure 1) was 0.030 in genomic DNA and
0.039 in cDNA.
The tested SNPs were all significantly associated with
allelic expression differences in peripheral blood, as
shown in Table 4. The most significant association with
expression was for rs6749447 (P = 9.9 × 10-4). This SNP is
located in intron 1 of STK39 and in our SA sample had
minor allele frequency 0.48 and D' 0.54 with the tran-
scribed SNP rs1061471 located in the 3' untranslated
region of the gene. Of the 33 included individuals who
were heterozygous for the transcribed SNP rs1061471, 14
were heterozygous for rs6749447. If a SNP affects expres-
sion in cis  then individuals heterozygous for that SNP
should show a greater allelic imbalance at the transcribed
SNP than homozygous individuals. Figure 1 shows the
allelic expression ratios grouped by whether individuals
are heterozygous or homozygous for rs6749447, com-
pared to the ratio seen in genomic DNA (where alleles are
present in a 1:1 ratio). There was no difference in allelic
expression ratios between genomic DNA and individuals
homozygous at rs6749447 (P = 0.07 using the Mann-
Whitney U test). However, individuals heterozygous for
rs6749447 have on average a higher allelic expression
Table 2: Allele frequencies of the SNPs typed in study participants
SNP Chromosome 
location
Alleles* Number genotyped HW P-value Frequency of putative risk allele
Caucasian cohort HapMap CEU SA cohort
rs3754777 2q24 (STK39 intron) G/A 1367 0.63 0.17 0.13 0.16
rs35929607 2q24 (STK39 intron) A/G 1361 0.79 0.19 NA 0.34
rs6749447 2q24 (STK39 intron) T/G 1369 0.32 0.29 0.28 0.52
rs4977950 9p21 (not within gene) G/C 1365 0.46 0.15 0.18 NA
* Major allele given first, putative risk allele for hypertension identified by Wang et al shown in bold; MAF, minor allele frequency; CEU, HapMap 
CEU Caucasian cohort; NA, not available; SA, South African.BMC Medical Genetics 2009, 10:135 http://www.biomedcentral.com/1471-2350/10/135
Page 6 of 9
(page number not for citation purposes)
ratio than the homozygous individuals (P = 0.005 using
the Mann-Whitney U test), which is consistent with a cis-
acting effect and also suggests that the overexpressing
allele is preferentially in phase with the G allele at the
transcribed locus. In individuals who were heterozygous
for rs6749447 on average the G allele of rs6749447
showed 13% overexpression compared to the T allele.
Once the effect of this SNP was adjusted for, the associa-
tion for the other SNPs no longer remained significant (as
shown in Table 4). Differences in allele frequencies and
patterns of linkage disequilibrium between the Caucasian
and South African populations are summarised in Table 2
and Figure 2.
Discussion
The STK39 SNPs reported to be associated with BP and
hypertension by Wang and colleagues [3] did not show a
significant association with BP in our British Caucasian
families. Other published GWAS and two large recent
meta-analyses did not identify associations achieving
genome-wide significance levels for STK39  polymor-
phisms and BP, despite powerful analyses of combined
cohorts involving 34,433 and 71,225 Caucasian individu-
als which successfully identified multiple other suscepti-
bility loci [9,10]. Although failure to achieve genome-
wide significance levels does not exclude an effect of this
locus on BP, any effect of sequence variation at STK39 on
BP is too small to be detected in our data and is perhaps
something particular to the Amish population. We also
found no association with BP for the chromosome 9p21.3
SNP rs4977950 which was the top signal in the GWAS by
Wang and colleagues (P = 9.1 × 10-8), and the only SNP to
achieve significance at the genome-wide threshold in their
study.
Inadequate power is an unlikely explanation for the lack
of association in this study as the maximum plausible
genetic effect for the typed SNPs on BP phenotypes, which
we calculated based on the observed mean effect and 95%
confidence intervals, was low in all cases and our data
exclude an effect as large as the 3 mmHg increase in systo-
Table 3: Effect sizes of tested SNPs
BP phenotype* N rs3754777 rs35929607 rs6749447 rs4977950
Clinic Systolic 1138 0.2 (-1.8, 2.3) 1 (-1, 2.9) 0.5 (-1.2, 2.2) 0 (-2.1, 2.1)
Clinic Diastolic 1130 -0.3 (-1.6, 1.1) 0.4 (-0.9, 1.7) 0.1 (-1, 1.2) 0.3 (-1.1,1.7)
Day Systolic 1134 -0.1 (-1.9, 1.7) -0.3 (-1.5, 2) 0.1 (-1.4, 1.6) 0.2 (-1.7, 2)
Day Diastolic 1133 -0.1 (-1.4, 1.1) 0.2 (-1, 1.4) 0.1 (-0.9, 1.2) 0.4 (-0.9, 1.7)
Night Systolic 903 0.4 (-1.4, 2.1) 0.9 (-0.8, 2.6) 0.7 (-0.7, 2.2) -0.2 (-2.1, 1.7)
Night Diastolic 902 0.7 (-0.5, 1.9) 1.1 (0, 2.3) 0.8 (-0.2, 1.8) -0.1 (-1.3, 1.2)
* All phenotypes log-transformed to approximately normalise distributions and adjusted for covariates before analysis; Effect sizes are the mmHg 
difference attributable to 1 copy of the risk (minor) allele, with 95% confidence interval given in brackets. P-value > 0.05 for all effects.
Effect of genotype at rs6749447 on allelic expression ratio of  the transcribed SNP rs1061471 Figure 1
Effect of genotype at rs6749447 on allelic expression 
ratio of the transcribed SNP rs1061471. Circles repre-
sent allelic expression ratio for each individual, with horizon-
tal bars representing the mean values for each group (shown 
alongside). The first column shows genomic DNA where the 
alleles are present in a 1:1 ratio, giving a mean ratio of 
approximately 1. The second column shows individuals who 
are homozygous for either allele of rs6749447. In this group, 
the cis-acting influence on expression from each allele is the 
same, giving a mean allelic expression ratio of approximately 
1 at the transcribed marker rs1061471 (P > 0.05 for the 
comparison with genomic DNA). The third column shows 
individuals who are heterozygous for rs6749447. In this 
group each of the two transcribed alleles is expressed at a 
different level, causing increased imbalance in allelic expres-
sion (P < 0.005 for the comparisons with genomic DNA and 
individuals homozygous for rs6749447).
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Table 4: Association of tested SNPs with allelic expression 
differences
SNP P-value P-value adjusted for rs6749447
rs35929607 0.02 0.39
rs3754777 0.006 0.71
rs6749447 0.001 -BMC Medical Genetics 2009, 10:135 http://www.biomedcentral.com/1471-2350/10/135
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lic BP per copy of the risk allele reported by Wang and col-
leagues in the Amish population. Families in the present
study were selected through a hypertensive proband and
had a higher proportion of hypertensive individuals and
wider distribution of BP values; this should increase the
power to detect an association with BP phenotypes com-
pared to the cohorts in the study by Wang and colleagues,
which were not selected for BP. The use of 24-hour ambu-
latory BP recordings in our study provides a more repro-
ducible assessment of "usual" BP and reduces
misclassification due to "white-coat" or masked hyperten-
sion that may occur with isolated clinic measurements
[14,15]; this should also reduce the noise and increase the
power of our study. The heritability of night-time BP
measures was significantly higher than clinic BP measures,
which should increase the power for detecting genetic
effects. It is a frequently observed phenomenon in genetic
epidemiology that studies first reporting a novel associa-
tion often show a more extreme odds ratio than subse-
quent replication studies [22]; if the effect size estimated
by Wang et al is an upwardly biased estimate this might
explain the negative association in our study and the other
reported GWAS. The effect due to STK39 alleles observed
by Wang et al was strongest in the Amish population and
substantially weaker in the other Caucasian cohorts tested
in their study. Our data suggest that the effect of the typed
STK39 SNPs on BP is at most modest in a UK Caucasian
population. If the reported association was caused by LD
between the typed SNPs and another functional variant,
then weaker LD in other populations, compared to the
Amish population, could account for the results; this is
particularly pertinent since closed founder populations
are expected to exhibit extensive LD. Heterogeneity
between the populations, including differences in popula-
tion history, recruitment strategy, and phenotypes (such
as the proportion of diabetics and hypertensives) might
also contribute to the differences in genetic associations
we have observed. Our analysis was performed using an
additive model because this was the model used to report
the most significant overall association by Wang and col-
leagues.
We have demonstrated that SNPs in the STK39 gene cor-
relate with in vivo allelic expression of this gene in periph-
eral blood cells. This corroborates and extends the
findings from reporter gene constructs in the study by
Wang and colleagues. Using a luciferase assay in HELA
and HEK293 cell lines they examined the effect on tran-
scription of two SNPs (rs12692877 and rs35929607) that
are in conserved elements and which were in complete LD
with two of the SNPs associated with BP in their GWAS in
the Amish population (rs6749447 and rs3754777 respec-
tively). They demonstrated that the G allele of
rs35929607, which was the allele reported to be associ-
ated with increased BP, was in isolation associated with a
greater than two-fold increase in transcriptional activity
compared to the A allele of this SNP, or either allele of
rs12692877. Such in vitro studies have limitations since
results depend on the constructs that are used and expres-
sion is considered outside of the normal chromatin and
cellular context, which may not reflect true expression in
complex tissues in vivo [16,18]. Allelic expression analysis
allows in vivo assessment of RNA transcripts in their native
environment and regulatory context, and by controlling
for trans-acting influences has high sensitivity to detect cis-
acting effects. We found a stronger association between
genotype and allelic expression for rs6749447 than for
rs35929607, with the G allele of rs6749447 associated
with a 13% increase in expression relative to the T allele.
However, if the effect of rs6749447 is not accounted for,
then our allelic expression analysis found that the G allele
of rs35929607 was significantly associated with increased
expression. This is consistent with the in vitro data from
Wang and colleagues, although the magnitude of the rel-
ative increase in our study was lower at 7%. The difference
in the magnitude of effect we observed compared to the in
Linkage disequilibrium between typed SNPs at the chromo- some 2q24 STK39 locus in Caucasian and South African par- ticipants Figure 2
Linkage disequilibrium between typed SNPs at the 
chromosome 2q24 STK39 locus in Caucasian and 
South African participants. Shading represents r2 values 
(r2 = 0 white, 0 < r2 < 1 shades of grey, r2 = 1 black). Num-
bers show D' values (and r2 values in brackets) between 
SNPs. NP, non-polymorphic in Caucasian population. Figure 
adapted from Haploview.
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vitro transfection studies is not surprising in view of the
fact that in vivo expression is likely to result from the inter-
action of multiple elements that modulate expression,
rather than just a single SNP.
AEI can only be assessed in individuals who are hetero-
zygous for a transcribed polymorphism in the gene of
interest - there were no suitable transcribed SNPs in STK39
in Caucasian populations and in the African cohort the
number of suitable heterozygotes was relatively small
because of a low minor allele frequency (7%) at the tran-
scribed SNP rs1061471. However, measurement of allelic
expression ratios within samples is very sensitive for
detection of cis-acting influences since trans-acting and
experimental factors are identical for each allele (because
comparisons are made within samples); this allows signif-
icant cis-acting effects to be detected in relatively few sam-
ples, as demonstrated in this study. Sensitivity of the
technique for the detection of significant effects in equiv-
alent sample sizes has been previously demonstrated
[23,24]. Populations of African-descent show on average
smaller regions of high LD and greater heterozygosity
compared to Caucasian populations [25,26], and there-
fore using a South African cohort increases the sensitivity
to separate the effects of different SNPs on expression.
This trans-ethnic approach using populations of African
descent has been shown to improve the fine mapping of
functional polymorphisms associated with quantitative
traits when strong LD between markers limits resolution
of the functional locus in Caucasian populations [27]. In
the case of STK39, using a population of different ethnic-
ity allowed allelic expression to be measured in the
absence of transcribed polymorphisms in the Caucasian
population. Correlation between STK39 SNPs and expres-
sion of this gene does not necessarily mean that these
SNPs will influence BP and the finding of an association
with STK39 expression in our study is therefore not at
odds with the lack of association with BP we observed.
A limitation of the present study is that expression was
only tested in white blood cells, rather than in a tissue of
potentially greater relevance to BP regulation. However,
many  cis-acting influences on gene expression are
expected to be the same in different cell types [28],
although tissue-specific differences have been described
[29]. In the case of STK39 this approach is supported by
the fact that rs35929607 genotype correlated with expres-
sion in immortalised cell lines derived from cervical
tumour cells (HELA) and embryonic kidney cells
(HEK293) in the study by Wang and colleagues, as well as
with expression in blood in the present study. However,
the effects may vary in other tissues. We have analysed the
SNPs influencing expression in a South African cohort of
mixed ethnicity, but the SNPs associated with expression
may vary in different populations due to differing allele
frequencies and LD patterns. Although the associations of
SNPs with STK39 expression that we observe are highly
statistically significant, the biological significance of these
findings is less certain, since we cannot say what impact
such an effect on expression has on disease risk. However,
even small differences in gene expression due to genetic
factors that are present throughout an individual's life-
time could contribute to differences in common late-
onset phenotypes such as hypertension and, as men-
tioned above, the effects may be greater in tissues related
to disease.
Future studies will be necessary to investigate the associa-
tion of other SNPs at the STK39 locus with BP, or to deter-
mine whether rare mutations at this locus contribute
significantly to population blood pressure variation, as
has been shown for other genes implicated in hyperten-
sion causation [30].
Conclusions
STK39 expression is modified by polymorphisms acting
in cis, but there is no evidence that these SNPs affecting
STK39 transcription are associated with BP in a British
Caucasian cohort.
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